TruScreen Share Placement

Company Announcement 24 March 2017

TruScreen Share Placement
TRUSCREEN LIMITED (TRU)
TruScreen Limited advises that it has issued new shares as follows:

Class of Security: Ordinary Shares (TRU)
Number issued:
25,562,500 ordinary shares at NZD 16 cents each
fully paid
Payment: Cash on subscription
Percentage of total Class of Securities
issued:
13.4% (of the total number of ordinary shares on
issue post completion of the issue)
Reason for the issue:
To strengthen the balance sheet, fund sales and
marketing initiatives, expand manufacturing
capabilities, and continue to improve the
performance of the device. In particular funding:
 for anticipated commercial opportunities in
China and India;

 growth in European and Latin American
markets;

 clinical and familiarisation trials as required
for product improvement and acceptance in
government programs;

 expansion of manufacturing facilities and
supply capabilities;

 build-up of inventory; and

 continued product refinement.
Authority of issue Director’s Resolution and NZAX Listing Rule 7.3.5

Terms of issue:
The new shares are credited as fully paid, and rank in
all respects equally with the shares already on issue
Total number of securities of the Class in
existence after the issue: 190,329,166
Date of issue: 24 March 2017

TRUSCREEN LIMITED




Martin Dillon
Chief Executive Officer

-ENDS-
For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer,
eMail: martindillon@truscreen.com
About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.